Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
ACRX closed down 7.76 percent on Tuesday, December 12, 2017, on 43 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||Down||Down||Down|
|See historical ACRX trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 12||Stochastic Reached Oversold||Other||0.00%|
|Dec 12||Outside Day||Range Expansion||0.00%|
|Dec 12||Wide Bands||Range Expansion||0.00%|
|Dec 12||Oversold Stochastic||Weakness||0.00%|
|Dec 11||Narrow Range Bar||Range Contraction||-7.76%|
|Dec 11||Wide Bands||Range Expansion||-7.76%|
|Dec 8||Wide Bands||Range Expansion||-6.67%|
|Dec 8||Oversold Stochastic||Weakness||-6.67%|
|Dec 7||180 Bearish Setup||Bearish Swing Setup||-8.84%|
|Dec 7||Narrow Range Bar||Range Contraction||-8.84%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACRX news...
|52 Week High||5.75|
|52 Week Low||1.55|
|200-Day Moving Average||2.7862|
|50-Day Moving Average||2.4754|
|20-Day Moving Average||2.1203|
|10-Day Moving Average||2.156|
|Average True Range||0.145|
|Chandelier Exit (Long, 3 ATRs )||1.915|
|Chandelier Exit (Short, 3 ATRs )||2.285|
|Upper Bollinger Band||2.3312|
|Lower Bollinger Band||1.9094|
|Percent B (%b)||0.12|
|MACD Signal Line||-0.0672|
|Market Cap||88.94 Million|
|Num Shares||45.4 Million|
|Price-to-Earnings (P/E) Ratio||-1.78|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||2.34|
|Resistance 3 (R3)||2.37||2.29||2.27|
|Resistance 2 (R2)||2.29||2.19||2.27||2.25|
|Resistance 1 (R1)||2.12||2.13||2.08||2.09||2.23|
|Support 1 (S1)||1.87||1.94||1.83||1.84||1.69|
|Support 2 (S2)||1.79||1.88||1.77||1.67|
|Support 3 (S3)||1.62||1.79||1.65|
|Support 4 (S4)||1.59|